Pfizer Inc.
Pharma · New York, New York · PFE
Open the interactive ecosystem map
Research-based biopharmaceutical company, New York, New York
Key facts
- Revenue $62.6B2025 · SEC 10-K · source
Strengths: Anti-infectives, Oncology, Cardiovascular, Inflammation and immunology, Rare diseases, Vaccines
Who pays Pfizer Inc.
None confirmed by two independent sources.
Who Pfizer Inc. pays
None confirmed by two independent sources.
Competitors
None confirmed by two independent sources.
Unconfirmed
Fewer than 2 independent sources. Shown with the source we found; treat as unverified.
- Revenue: Full-year 2025 revenue guidance revised sec.gov
- McKesson CorporationPays them · Drug wholesaler, top customer25% of Pfizer's 2025 total revenue, per its FY2025 10-K.sec.gov
- Cencora, Inc.Pays them · Drug wholesaler, customer16% of Pfizer's 2025 total revenue, per its FY2025 10-K.sec.gov
- Cardinal Health, Inc.Pays them · Drug wholesaler, customer13% of Pfizer's 2025 total revenue, per its FY2025 10-K.sec.gov
- U.S. federal government (incl. CDC)Pays them · Vaccine buyerVaccines in the U.S. are primarily sold directly to the federal government, including the CDC.sec.gov
- Pharmacy benefit managers and managed care plansPays them · Rebate and discount counterpartiesPfizer has contracts with managed care programs or PBMs, providing rebates on medicines used.sec.gov
- Lonza Group AGThey pay · CDMO and technology licensorCritical CDMO partner for years of biologic drug substance manufacturing.procurementmag.com
- Catalent IncThey pay · Contract manufacturerPart of a network of around 200 outside contractors Pfizer tapped in 2020.cnbc.com
- Thermo Fisher Scientific IncThey pay · Contract manufacturerAmong outside contractors Pfizer used for production, per a 2020 report.business-standard.com
- SAPThey pay · Enterprise software vendorPowers Pfizer's global procurement and supply chain infrastructure.procurementmag.com
- IBMThey pay · IT and consulting providerStrategic infrastructure and consulting provider for hybrid cloud workloads.procurementmag.com
- BiovacThey pay · Contract manufacturer, COVID vaccinePerforms manufacturing and distribution in Pfizer and BioNTech's COVID-19 vaccine supply chain.sec.gov
- Pfizer CentreOneThey pay · Internal CDMO armPfizer's own contract manufacturing unit, with more than 35 sites.contractpharma.com
- Merck & Co.Competes with · Pharmaceutical companyOverlaps in oncology, vaccines and hospital acute carehudson-labs.com
- AbbVie Inc.Competes with · Biopharmaceutical companyOverlaps in immunology, oncology and neurosciencehudson-labs.com
- Johnson & JohnsonCompetes with · Pharmaceutical and medtech companyOverlaps in oncology, immunology and neurosciencehudson-labs.com
- Eli Lilly and CompanyCompetes with · Pharmaceutical companyCompetes in cardiometabolic and incretin medicineshudson-labs.com
- Bristol Myers SquibbCompetes with · Pharmaceutical companyOverlaps in oncology, immunology and cardiovascularhudson-labs.com
- Novartis AGCompetes with · Pharmaceutical companyCompetes across numerous therapeutic areasmarketing91.com
- AstraZenecaCompetes with · Biopharmaceutical companyOverlaps in oncology and chronic disease medicinesmarketing91.com
- Amgen Inc.Competes with · Biopharmaceutical companyDirect competition in biologics and biosimilarshudson-labs.com
In the news, last 14 days
- Pfizer Deal With Blackstone Secures Up to $1.5B to Bankroll GLP-1 Drug TrialsMedCity News, Nov 12Blackstone Life Sciences is placing a bet on Pfizer’s berobenatide, a GLP-1 drug designed for monthly dosing. This GLP-1 drug comes from Metsera, which Pfizer acquired last year in a $10 billion deal.
- Blackstone bets $1.5B on Pfizer’s obesity drugBioPharma Dive, Nov 12The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug's previous owner, Metsera.
- STAT+: Blackstone backs Pfizer's bet on monthly obesity treatmentSTAT, Nov 12
- Pfizer secures up to $1.5B for obesity drug developmentBecker's Hospital Review, Nov 12Pfizer has reached a co-funding agreement with Blackstone Life Sciences that will provide up to $1.5 billion in development funding through 2028 for its investigational obesity drug berobenatide.
- Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera assetBioSpace, Nov 12
- Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launchFierce Biotech, Nov 12
SEC filings
- PFIZER INC · 8-K · Items 5.02,9.012026-11-03
- PFIZER INC · 10-Q2026-11-03
- PFIZER INC · 8-K · Items 2.02,9.012026-11-03
Relationships were compiled by AI from public sources on Nov 12, 2026 AI. Each number shows how many sources back it; a range means sources differ, and readings far off the rest are dropped. Relationships listed above Unconfirmed have 2 independent sources, a filing, or a party's own announcement. Hospitals and zip codes come from CMS.
Follow this page by RSS in any feed reader, like NetNewsWire or Feedly.
Actari is a free healthcare news and data terminal. Stories here are reported by the outlets named and link to them; Actari is not affiliated with the organizations in the news. AI reads are interpretation and can be wrong; nothing here is medical, legal or investment advice. Terms · Corrections and removal